Combination of methylprednisolone and minocycline synergistically improves experimental autoimmune encephalomyelitis in C57 BL/6 mice

Journal of Neuroimmunology

Volumn 226, Issue 1-2, 2010, Pages 104-109

  Chen, Xiaohong ^a   Pi, Rongbiao ^a   Liu, Mei ^a   Ma, Xiaomeng ^a   Jiang, Ying ^a   Liu, Yingying ^a   Mao, Xuexuan ^a   Hu, Xueqiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Experimental autoimmune encephalomyelitis; Interferon gamma; Interleukin 4; Methylprednisolone; Minocycline; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; METHYLPREDNISOLONE; MINOCYCLINE; UNCLASSIFIED DRUG; URBASON1; ANTIINFECTIVE AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; FREUND ADJUVANT; GLYCOPROTEIN; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TH2 CELL; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; PROCEDURES;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FREUND'S ADJUVANT; GLYCOPROTEINS; INTERFERON-GAMMA; INTERLEUKIN-4; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; MINOCYCLINE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RNA, MESSENGER; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 77956343587     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.05.039     Document Type: Article

References (38)

1. Almawi W.Y., Beyhum H.N., Rahme A.A., Rieder M.J. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 1996, 60:563-572.
2. Begolka W.S., Vanderlugt C.L., Rahbe S.M., Miller S.D. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 1998, 161:4437-4446.
3. Brundula V., Rewcastle B., Metz L., Bernard C.C., Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a novel therapeutic for multiple sclerosis. Brain 2002, 125:1297-1308.
4. Chen X.H., Hu X.Q., Zou Y., Pi R.P., Liu M., Wang T.Q., Zheng X.P., Liu M., Lin M.D., Liu P.Q., Tao L. Combined treatment with minocycline and prednisone attenuates experimental autoimmuneencephalomyelitis in C57 BL/6 mice. J. Neuroimmunol. 2009, 210:22-29.
5. Conway D., Cohen J.A. Combination therapy in multiple sclerosis. Lancet Neurol. 2010, 9:299-308.
6. Diem R., Sättler M.B., Merkler D., Demmer I., Maier K., Stadelmann C., Ehrenreich H., Bähr M. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005, 128:375-385.
7. Eng L.F., D'Amelio F.E., Smith M.E. Dissociation of GFAP intermediate filaments in EAE: observations in the lumbar spinal cord. Glia 1989, 2:308-317.
8. Gayo A., Mozo L., Suarez A., Tunon A., Lahoz C., Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 1998, 85:122-130.
9. Gold R. Combination therapies in multiple sclerosis. J. Neurol. 2008, 255(Suppl. 1):51-60.
10. Giuliani F., Metz L.M., Wilson T., Fan Y., Bar-Or A., Yong V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 2005, 158:213-221.
11. Giuliani F., Fu S.A., Metz L.M., Yong V.W. Effective combination of minocycline and interferon-β in a model of multiple sclerosis. J. Neuroimmunol. 2005, 165:83-91.
12. Giuliani F., Hader W., Yong V.W. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J. Leukoc. Biol. 2005, 78:135-143.
13. Hofstetter H.H., Shive C.L., Forsthuber T.G. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 2002, 169:117-125.
14. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 2005, 106:163-177.
15. Issazadeh S., Mustafa M., Ljungdahl A., Hojeberg B., Dagerlind A., Elde R., Olsson T. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J. Neurosci. Res. 1995, 40:579-590.
16. Issazadeh S., Lorentzen J.C., Mustafa M.I., Hojeberg B., Mussener A., Olsson T. Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor-beta. J. Neuroimmunol. 1996, 69:103-115.
17. Kuerten S., Kostova-Bales D.A., Frenzel L.P., Tigno J.T., Tary-Lehmann M., Angelov D.N., Lehmann P.V. MP4-and MOG: 35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J. Neuroimmunol. 2007, 189:31-40.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001, 25:402-408.
19. Luccarini I., Ballerini C., Biagioli T., Biamonte F., Bellucci A., Rosi M.C., Grossi C., Massacesi L., Casamenti F. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp. Neurol. 2008, 211:214-226.
20. Metz L.M., Zhang Y., Yeung M., Patry D.G., Bell R.B., Stoian C.A., Yong V.W., Patten S.B., Duquette P., Antel J.P., Mitchell J.R. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 2004, 55:756.
21. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
22. Nikodemova M., Lee J.E., Fabry Z., Duncan I. Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord. J. Neuroimmunol. 2010, 219:33-37.
23. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
24. O'Garra A., Steinman L., Gijbels K. CD4+T-cell subsets in autoimmunity. Curr. Opin. Immunol. 1997, 9:872-883.
25. O'Neill E.J., Day M.J., Wraith D.C. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J. Neuroimmunol. 2006, 178:1-8.
26. Paintlia A.S., Paintlia M.K., Singh I., Singh A.K. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp. Neurol. 2008, 214:168-180.
27. Paintlia A.S., Paintlla M.K., Singh I., Skoff R.B., Singh A.K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009, 57:182-193.
28. Popovic N., Schubart A., Goetz B.D., Zhang S.C., Linington C., Duncan I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 2002, 51:215-223.
29. Pozzilli C., Marinelli F., Romano S., Bagnato F. Corticosteroids treatment. J. Neurol. Sci. 2004, 223:47-51.
30. Renno T., Taupin V., Bourbonniere L., Verge G., Tran E., De Simone R. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol. Cell Neurosci. 1998, 12:376-389.
31. Sättler, M.B., Bähr, M., in press. Future neuroprotective strategies. Exp. Neurol. doi:10.1016/j.expneurol.2009.08.016.
32. Sorensen P.S., Mellgren S.I., Svenningsson A., Elovaara I., Frederiksen J.L., Beiske A.J., Myhr K.M., Seaard L.V., Olsen I.C., Sandberg-Wollheim M. NORdic, trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009, 8:519-529.
33. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. U. S. A. 1996, 193:2253-2256.
34. Tischner D., Reichardt H.M. Glucocorticoids in the control of neuroinflammation. Mol. Cell. Endocrinol. 2007, 275:62-70.
35. Tselis A., Perumal J., Caon C., Hreha S., Chinga W., Din M., Stavern G.V., Khan O. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur. J. Neurol. 2008, 15:1163-1167.
36. Tullman M.J., Lublin F.D. Combination therapy in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2005, 5:245-248.
37. Virley D.J. Developing therapeutics for the treatment of multiple sclerosis. J. NeuroRx. 2005, 2:638-649.
38. Yong V.W., Wells J., Giuliani F., Casha S., Power C., Metz L.M. The promise of minocycline in neurology. Lancet Neurol. 2004, 3:744-751.